Medis is proud to announce a new partnership with Neurim Pharmaceuticals Ltd. Our exclusive distribution agreement for the commercialization of Slenyto® represents an important milestone for both companies.
Slenyto® is the first and only prescription medicine indicated for the treatment of insomnia in children and adolescents aged 2 to 18 years with (ASD Autism Spectrum Disorder) and/or Smith-Magenis syndrome for whom sleep hygiene measures have been inadequate. Slenyto® is a paediatric prolonged-release melatonin formulation that uniquely mimics endogenous melatonin secretion.
The partnership agreement includes exclusive rights to promote the product in Austria, Croatia, Czech Republic, Hungary, Slovakia and Slovenia, leveraging Medis’ strong sales and marketing capabilities and experience in successfully bringing innovative medicines to the CEE region.
Martina Perharič, Medis CEO, added:
Up to 75% of children with autism have sleep problems. Poor sleep can exacerbate behavioural problems and leave children and families exhausted. We are pleased and honoured that our expertise in the already well-established neurology portfolio will bring added value to the patients and families in need.
